This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
Merck pill cuts COVID hospitalizations by half in study
Merck and Ridgeback Biotherapeutics reported molnupiravir reduced hospitalization and death by about 50 percent in adults with mild to moderate COVID-19 at higher risk. In a 775-patient trial, 7.3% on the drug were hospitalized or died at 30 days versus 14.1% on placebo. no drug-group deaths occurred after 30 days. The company plans FDA submission. experts caution vaccines remain essential.
MENTIONED IN THIS ARTICLE
Washington
Merck
U.S
U.S. Food and Drug Administration
William Schaffner
Vanderbilt University
Ridgeback Biotherapeutics
FDA
Schaffner
Associated Press Health and Science Department
Howard Hughes Medical Institute
Department of Science Education
Merck & CO